Welcome to our dedicated page for Sol Gel Tech SEC filings (Ticker: SLGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sol-Gel Technologies Ltd. (NASDAQ: SLGL) files reports with the U.S. Securities and Exchange Commission as a foreign private issuer, primarily through annual reports on Form 20-F and current reports on Form 6-K. These SEC filings document the company’s activities as a dermatology-focused developer of topical drug products such as TWYNEO and EPSOLAY and pipeline candidates including SGT-610 and SGT-210.
On this page, you can review Sol-Gel’s Form 6-K submissions that furnish press releases and, in some cases, unaudited condensed consolidated financial statements for specific periods. These filings cover topics such as quarterly and semi-annual financial results, updates on the Phase 3 clinical trial of SGT-610 for Gorlin syndrome, developments in the Phase 1b study of SGT-210 in Darier disease, licensing and product purchase agreements for EPSOLAY and TWYNEO, and corporate actions like the 10-for-1 reverse share split and the transfer of the company’s listing to the Nasdaq Capital Market.
Sol-Gel’s filings also include proxy materials for annual shareholder meetings, auditor appointments, board and executive approvals and other governance matters. Certain press releases attached as exhibits to Form 6-K are expressly incorporated by reference into the company’s registration statements on Form S-8 and Form F-3, as noted in the filings. For investors analyzing SLGL, the 20-F annual report and accompanying risk factor discussions provide additional context on clinical, regulatory, financial and market risks associated with the company’s dermatology portfolio and rare disease programs.
Stock Titan’s SEC filings page for SLGL presents these documents with real-time updates from EDGAR and AI-powered summaries that highlight key points in lengthy disclosures. This helps readers quickly understand Sol-Gel’s financial position, clinical trial status, licensing arrangements and corporate actions without manually parsing every line of each 6-K or 20-F filing.
Itzik Yosef filed a Form 144 to sell 1,170 ordinary shares of SLGL. The filing lists the proposed sale date as 02/23/2026 and indicates the transaction method as Cash Upon Exercise. The filing also records a prior sale of 1,168 ordinary shares on 01/07/2026.
Opaleye Management Inc., a more than ten percent owner of Sol-Gel Technologies Ltd., reported an indirect open-market purchase of 291 ordinary shares of Sol-Gel on February 13, 2026 at a price of $63.00 per share, through Opaleye, L.P.
After this transaction, Opaleye, L.P. held 450,335 ordinary shares, and a separately managed account overseen by Opaleye held 10,000 ordinary shares. Opaleye Management Inc. disclaims beneficial ownership of these shares except to the extent of its pecuniary interest.
Sol-Gel Technologies Ltd. reported an amended insider filing for Opaleye Management Inc., a more than 10% holder. Through Opaleye, L.P., a related fund, there was an open-market purchase of 100 ordinary shares at a price of 58.0000 per share on 2026-02-02.
After this trade, Opaleye, L.P. held 450,044 shares, and a separately managed account associated with Opaleye held 10,000 shares, both reported as indirect ownership. The amendment states it corrects the previously reported beneficially owned share count due to a clerical error, and Opaleye Management Inc. disclaims beneficial ownership except to the extent of its pecuniary interest.
Sol-Gel Technologies Ltd. had an insider ownership update involving entities managed by Opaleye Management Inc. On February 2, 2026, Opaleye, L.P. purchased 100 ordinary shares of Sol-Gel at $58 per share, bringing its indirectly held position to 450,944 ordinary shares. A separately managed account overseen by Opaleye Management holds an additional 10,000 ordinary shares indirectly. Opaleye Management Inc. states that it may be deemed to beneficially own these securities but disclaims beneficial ownership beyond its pecuniary interest.
Opaleye Management Inc., a 10% owner of Sol-Gel Technologies Ltd., reported an indirect open‑market purchase of 100 ordinary shares on January 27, 2026 at $57.05 per share. These shares are held by Opaleye, L.P., bringing that fund’s reported holdings to 449,944 shares. A separately managed account associated with Opaleye holds an additional 10,000 shares. Opaleye Management Inc. states it may be deemed to beneficially own these securities through its roles with the fund and managed account, but disclaims beneficial ownership except to the extent of its pecuniary interest.
Opaleye Management Inc., a 10% owner of Sol-Gel Technologies Ltd. (SLGL), reported January open-market share purchases made through affiliated investment vehicles. On January 22, 2026, Opaleye, L.P. bought 2,173 ordinary shares at a weighted average price of $56.5681 per share, and on January 23, 2026 it bought another 1,151 shares at a weighted average price of $55.9809. After these transactions, 449,844 ordinary shares were held indirectly through Opaleye, L.P., and an additional 10,000 shares were held indirectly via a separately managed account. The filing notes that prices reflect weighted averages across multiple trades within disclosed price ranges and that Opaleye Management Inc. disclaims beneficial ownership beyond its pecuniary interest.
SLGL security holder Itzik Yosef filed a Form 144 notice to sell 713 ordinary shares. The planned sale is to be executed through Oppenheimer & Co. Inc. on or about 01/14/2026, with an aggregate market value of $44,876.22, and the shares are listed on Nasdaq. The filing states that 27,857,620 ordinary shares were outstanding.
The 713 shares were acquired on 08/02/2016 under an employee stock option plan from the issuer, with cash payment upon option exercise dated 01/15/2026. In the past three months, the same seller has reported sales of 398, 54 and 3 ordinary shares on 01/07/2026, 01/12/2026 and 01/13/2026, for gross proceeds of $19,974.27, $3,513.01 and $195.00, respectively.
Sol-Gel Technologies Ltd. filed a Form 6-K as a foreign private issuer to furnish a press release issued on December 17, 2025. The press release provides an update following unblinding of the company’s Phase 1b study of SGT-210 in Darier Disease.
Exhibit 99.1, which contains the press release (other than its third paragraph), is incorporated by reference into Sol-Gel’s existing Registration Statements on Form S-8 (Registration Nos. 333-223915, 333-270477 and 333-286820) and its Registration Statement on Form F-3 (Registration No. 333-286822).
Opaleye Management Inc., reporting as a 10% owner of Sol-Gel Technologies Ltd., disclosed a small indirect purchase of ordinary shares. On 12/12/2025, 87 ordinary shares with a par value of NIS 1.00 per share were acquired at a reported price of $40. After this transaction, 371,795 ordinary shares are held indirectly through Opaleye, L.P. and 10,000 ordinary shares are held indirectly through a separately managed account. Opaleye Management Inc. states it may be deemed to beneficially own these securities through its roles with the fund and managed account, but disclaims beneficial ownership except to the extent of its pecuniary interest.
Opaleye Management Inc. reported open market purchases of Sol-Gel Technologies Ltd. (SLGL) ordinary shares. On 11/24/2025, an affiliated fund bought 6 ordinary shares at $35.5 per share, and on 11/26/2025 it bought another 943 shares at a weighted average price of $40.00. Following these transactions, the fund is shown as beneficially owning 364,100 Sol-Gel ordinary shares, with an additional 10,000 shares held in a separately managed account. Opaleye Management Inc. states that it may be deemed to beneficially own these securities through its roles with the fund and the managed account and disclaims beneficial ownership except to the extent of its pecuniary interest.